Treatment of parkinson's disease in thailand: Review of the literature and practical recommendations

Journal of the Medical Association of Thailand

Volumn 92, Issue 1, 2009, Pages 142-154

  Bhidayasiri, Roongroj ^a   Ling, Helen ^b  

^a KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Deep brain stimulation; Motor complications; Parkinson's disease

Indexed keywords

ACA; ACAMED; AMANTADINE; ANTACID AGENT; BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOMPERIDONE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; HYPOCHOLESTEROLEMIC AGENT; IRON; JULAB; LAXATIVE; LEVODOPA; LEVODOPA METHYL ESTER; PIRIBEDIL; PRAMIPEXOLE; PYRIDOXINE; RASAGILINE; ROPINIROLE; SELEGILINE; TOLCAPONE; TRIHEXYPHENIDYL; TRIVASTRAL RETARD; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AGRANULOCYTOSIS; ARTICLE; BEDTIME DOSAGE; BLURRED VISION; BRAIN DEPTH STIMULATION; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DAILY LIFE ACTIVITY; DARK URINE COLOR; DIARRHEA; DIZZINESS; DROWSINESS; DRUG BIOAVAILABILITY; DYSKINESIA; DYSTONIA; EDEMA; HALLUCINATION; HEADACHE; HEPATITIS; HUMAN; HYPOTENSION; INSOMNIA; INTRAOCULAR PRESSURE; MORNING DOSAGE; MOTOR PERFORMANCE; MYDRIASIS; NAUSEA; NERVOUSNESS; NEUROPROTECTION; PALLIDOTOMY; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PATIENT SELECTION; PRACTICE GUIDELINE; QUALITY OF LIFE; SIDE EFFECT; SLEEP ATTACK; SOMNOLENCE; SYMPTOM; THAILAND; URINE RETENTION; VALVULAR FIBROSIS; VOMITING; WEAKNESS; XEROSTOMIA;

ANTIPARKINSON AGENTS; DEEP BRAIN STIMULATION; DOPAMINE AGONISTS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; THAILAND;

EID: 59649104441     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. World Health Organization. Neurological disorders: Public health challenges. Geneva: WHO; 2006.
2. Lang AE, Lozano AM. Parkinson's disease. Second of two parts. N Engl J Med 1998; 339: 1130-43.
3. Lang A E, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med 1998; 339: 1044-53.
4. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
5. Forno L S. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996; 55: 259-72.
6. Pahwa R, Factor SA, Lyons K E, Ondo W G, Gronseth G, Bronte-Stewart H, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence- based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 983-95.
7. Miyasaki J M, Shannon K, Voon V, Ravina B, Kleiner- Fisman G, Anderson K, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 996-1002.
8. Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner W J. Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 968-75.
9. Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner W J. Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 976-82.
10. Goetz C G, Poewe W, Rascol O, Sampaio C. Evidence- based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005; 20: 523-39.
11. Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A, Kanovsky P, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur J Neurol 2006; 13: 1186-202.
12. Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A, Kanovsky P, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol 2006; 13: 1170-85.
13. Effect of deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med 1989; 321: 1364-71.
14. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002; 59: 1937-43.
15. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287: 1653-61.
16. Whone A L, Watts R L, Stoessl A J, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003; 54: 93-101.
17. Shannon KM, Bennett J P Jr, Friedman J H. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology 1997; 49: 724-8.
18. Adler C H, Sethi K D, Hauser R A, Davis TL, Hammerstad J P, Bertoni J, et al. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 1997; 49: 393-9.
19. Barone P, Bravi D, Bermejo- Pareja F, Marconi R, Kulisevsky J, Malagu S, et al. Pergolide mono- therapy in the treatment of early P D: a randomized, controlled study. Pergolide Monotherapy Study Group. Neurology 1999; 53: 573-9.
20. Jankovic J, Watts R L, Martin W, Boroojerdi B. Transdermal rotigotine: double-blind, placebo- controlled trial in Parkinson disease. Arch Neurol 2007; 64: 676-82.
21. Rascol O, Brooks D J, Korczyn AD, De Deyn PP, Clarke C E, Lang A E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342: 1484-91.
22. Holloway R G, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61: 1044-53.
23. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007; 356: 29-38.
24. Flowers CM, Racoosin J A, Lu S L, Beitz J G. The US Food and Drug Administration's registry of patients with pergolide- associated valvular heart disease. Mayo Clin Proc 2003; 78: 730-1.
25. Horvath J, Fross RD, Kleiner- Fisman G, Lerch R, Stalder H, Liaudat S, et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 2004; 19: 656-62.
26. Baseman D G, O'Suilleabhain P E, Reimold S C, Laskar S R, Baseman J G, Dewey R B Jr. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 2004; 63: 301-4.
27. Newman- Tancredi A, Cussac D, Quentric Y, Touzard M, Verriele L, Carpentier N, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther 2002; 303: 815-22.
28. Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363: 1179-83.
29. Van Camp G, Flamez A, Cosyns B, Goldstein J, Perdaens C, Schoors D. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology 2003; 61: 859-61.
30. U.S. Food and Drug Administration. FDA announces voluntary withdrawal of pergolide products [hompage on the Internet]. 2007 [cited 2008 Dec 5]. Available from: http://www.fda.gov/bbs/topics/news/2007/new01596.html
31. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498-508.
32. Lees A J, Katzenschlager R, Head J, Ben Shlomo Y. Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology 2001; 57: 1687-94.
33. Kulisevsky J, Lopez- Villegas D, Garcia-Sanchez C, Barbanoj M, Gironell A, Pascual- Sedano B. A six- month study of pergolide and levodopa in de novo Parkinson's disease patients. Clin Neuropharmacol 1998; 21: 358-62.
34. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community- based study. Brain 2000; 123(Pt 11): 2297-305.
35. Ahlskog J E, Muenter MD. Frequency of levodopa- related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16: 448-58.
36. Durso R, Evans J E, Josephs E, Szabo G, Evans B, Fernandez H H, et al. Variable absorption of carbidopa affects both peripheral and central levodopa metabolism. J Clin Pharmacol 2000; 40: 854-60.
37. Dingemanse J, Kleinbloesem C H, Zurcher G, Wood ND, Crevoisier C. Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics. Br J Clin Pharmacol 1997; 44: 41-8.
38. Olanow C W, Obeso JA, Stocchi F. Continuous dopamine- receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006; 5: 677-87.
39. Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005; 62: 905-10.
40. Goetz C G. Treatment of advanced Parkinson's disease: an evidence-based analysis. Adv Neurol 2003; 91: 213-28.
41. Bhidayasiri R, Truong D D. Reply from the authors: Motor complications in Parkinson disease: Clinical manifestations and management. J Neurol Sci 2008; 273: 156-7.
42. Nutt J G. Levodopa- induced dyskinesia: review, observations, and speculations. Neurology 1990; 40: 340-5.
43. Brooks D J, Agid Y, Eggert K, Widner H, Ostergaard K, Holopainen A. Treatment of end - of - dose wearing- off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Eur Neurol 2005; 53: 197-202.
44. Rinne UK, Larsen J P, Siden A, Worm- Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998; 51: 1309-14.
45. Rajput AH, Martin W, Saint-Hilaire M H, Dorflinger E, Pedder S. Tolcapone improves motor function in parkinsonian patients with the "wearing- off phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997; 49: 1066-71.
46. Assal F, Spahr L, Hadengue A, Rubbia-Brandt L, Burkhard PR. Tolcapone and fulminant hepatitis. Lancet 1998; 352: 958.
47. Hauser R A. Levodopa/carbidopa/entacapone (Stalevo). Neurology 2004; 62: S64-71.
48. Myllyla V, Haapaniemi T, Kaakkola S, Kinnunen E, Hartikainen P, Nuutinen J, et al. Patient satisfaction with switching to Stalevo: an open-label evaluation in P D patients experiencing wearing- off (Simcom Study). Acta Neurol Scand 2006; 114: 181-6.
49. Olanow CW, Fahn S, Muenter M, Klawans H, Hurtig H, Stern M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994; 9: 40-7.
50. Lieberman A, Olanow C W, Sethi K, Swanson P, Waters C H, Fahn S, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology 1998; 51: 1057-62.
51. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo- controlled, parallel-group study. Neurology 1997; 49: 162-8.
52. LeWitt PA, Lyons K E, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 2007; 68: 1262-7.
53. Kurth MC, Tetrud JW, Irwin I, Lyness WH, Langston J W. Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study. Neurology 1993; 43: 1036-9.
54. Golbe LI, Lieberman AN, Muenter MD, Ahlskog J E,
55. Gopinathan G, Neophytides AN, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol 1988; 11: 45-55.
56. Hauser RA, Russ H, Haeger DA, Bruguiere- Fontenille M, Muller T, Wenning GK. Patient evaluation of a home diary to assess duration and severity of dyskinesia in Parkinson disease. Clin Neuropharmacol 2006; 29: 322-30.
57. Shoulson I, Oakes D, Fahn S, Lang A, Langston J W, LeWitt P, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002; 51: 604-12.
58. Hauser R A, Olanow C W. Orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson's disease. Mov Disord 1993; 8: 512-4.
59. Linazasoro G. Anticholinergics and dyskinesia. Mov Disord 1994; 9: 689.
60. Snow B J, Macdonald L, Mcauley D, Wallis W. The effect of amantadine on levodopa- induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 2000; 23: 82-5.
61. Thomas A, Iacono D, Luciano A L, Armellino K, Di Iorio A, Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75: 141-3.
62. Verhagen ML, Del Dotto P, van den MP, Fang J, Mouradian MM, Chase T N. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998; 50: 1323-6.
63. Durif F, Debilly B, Galitzky M, Morand D, Viallet F, Borg M, et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo- controlled study. Neurology 2004; 62: 381-8.
64. Poewe W H, Lees A J, Stern GM. Dystonia in Parkinson's disease: clinical and pharmacological features. Ann Neurol 1988; 23: 73-8.
65. Melamed E. Early-morning dystonia. A late side effect of long-term levodopa therapy in Parkinson's disease. Arch Neurol 1979; 36: 308-10.
66. Odin P, Oehlwein C, Storch A, Polzer U, Werner G, Renner R, et al. Efficacy and safety of high-dose cabergoline in Parkinson's disease. Acta Neurol Scand 2006; 113: 18-24.
67. Barone P, Amboni M, Vitale C, Bonavita V. Treatment of nocturnal disturbances and excessive daytime sleepiness in Parkinson's disease. Neurology 2004; 63: S35-S38.
68. Pahwa R, Busenbark K, Huber SJ, Michalek D. Hubble J P, Koller WC. Clinical experience with controlled-release carbidopa/levodopa in Parkinson's disease. Neurology 1993; 43: 677-81.
69. Qureshi GA, Qureshi A A, Memon SA, Parvez S H. Impact of selenium, iron, copper and zinc in on/off Parkinson's patients on L- dopa therapy. J Neural Transm Suppl 2006; 229-36.
70. Leon AS, Spiegel HE. The effect of antacid administration on the absorption and metabolism of levodopa. J Clin Pharmacol New Drugs 1972; 12: 263-7.
71. Pfeiffer R, Ebadi M. On the mechanism of the nullification of CNS effects of L- DOPA by pyri- doxine in Parkinsonian patients. J Neurochem 1972; 19: 2175-81.
72. Pierantozzi M, Pietroiusti A, Brusa L, Galati S, Stefani A, Lunardi G, et al. Helicobacter pylori eradication and l- dopa absorption in patients with PD and motor fluctuations. Neurology 2006; 66: 1824-9.
73. Pierantozzi M, Pietroiusti A, Galante A, Sancesario G, Lunardi G, Fedele E, et al. Helicobacter pylori- induced reduction of acute levodopa absorption in Parkinson's disease patients. Ann Neurol 2001; 50: 686-7.
74. Contin M, Riva R, Martinelli P, Albani F, Baruzzi A. Effect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled release [corrected] in parkinsonian patients. Eur J Clin Pharmacol 1998; 54: 303-8.
75. Baruzzi A, Contin M, Riva R, Procaccianti G, Albani F, Tonello C, et al. Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. Clin Neuropharmacol 1987; 10: 527-37.
76. Leenders KL, Poewe WH, Palmer AJ, Brenton DP, Frackowiak RS. Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 1986; 20: 258-62.
77. Nutt J G, Woodward WR, Hammerstad J P, Carter J H, Anderson J L. The "on-off' phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med 1984; 310: 483-8.
78. Brogden R N, Carmine A A, Heel R C, Speight T M, Avery G S. Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs 1982; 24: 360-400.
79. Soykan I, Sarosiek I, Shifflett J, Wooten GF, McCallum RW. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease. Mov Disord 1997; 12: 952-7.
80. Nutt J G, Woodward W R. Levodopa pharmaco-kinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 1986; 36: 739-44.
81. Colosimo C, Merello M, Hughes AJ, Sieradzan K, Lees AJ. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the patho- genesis of the on-off phenomenon. J Neurol Neurosurg Psychiatry 1996; 60: 634-7.
82. Pincus J H, Barry KM. Plasma levels of amino acids correlate with motor fluctuations in parkinsonism. Arch Neurol 1987; 44: 1006-9.
83. Pincus J H, Barry K. Influence of dietary protein on motor fluctuations in Parkinson's disease. Arch Neurol 1987; 44: 270-2.
84. Weaver F, Follett K, Hur K, Ippolito D, Stern M. Deep brain stimulation in Parkinson disease: a metaanalysis of patient outcomes. J Neurosurg 2005; 103: 956-67.
85. Kleiner-Fisman G, Herzog J, Fisman DN, Tamma F, Lyons K E, Pahwa R, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 2006; 21 (Suppl 14): S290-304.
86. Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schafer H, Botzel K, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006; 355: 896-908.